JiangXi Tianxin Pharm Co Ltd (603235) - Total Assets
Based on the latest financial reports, JiangXi Tianxin Pharm Co Ltd (603235) holds total assets worth CN¥6.25 Billion CNY (≈ $915.22 Million USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check 603235 cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
JiangXi Tianxin Pharm Co Ltd - Total Assets Trend (2020–2025)
This chart illustrates how JiangXi Tianxin Pharm Co Ltd's total assets have evolved over time, based on quarterly financial data. Check JiangXi Tianxin Pharm Co Ltd cash earnings quality to evaluate the quality of earnings relative to operating cash generation.
JiangXi Tianxin Pharm Co Ltd - Asset Composition Analysis
Current Asset Composition (December 2025)
JiangXi Tianxin Pharm Co Ltd's total assets of CN¥6.25 Billion consist of 45.0% current assets and 55.0% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 25.4% |
| Accounts Receivable | CN¥293.97 Million | 4.8% |
| Inventory | CN¥569.89 Million | 9.2% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥188.48 Million | 3.1% |
| Goodwill | CN¥0.00 | 0.0% |
Asset Composition Trend (2020–2025)
This chart illustrates how JiangXi Tianxin Pharm Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see 603235 market cap overview.
Key Asset Composition Facts
- Current vs. Non-Current Assets: JiangXi Tianxin Pharm Co Ltd's current assets represent 45.0% of total assets in 2025, a decrease from 56.5% in 2020.
- Cash Position: Cash and equivalents constituted 25.4% of total assets in 2025, down from 35.0% in 2020.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 3.0% of total assets, an increase from 2.0% in 2020.
- Asset Diversification: The largest asset category is inventory at 9.2% of total assets.
JiangXi Tianxin Pharm Co Ltd Competitors by Total Assets
Key competitors of JiangXi Tianxin Pharm Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Nestle S.A.
SW:NESN
|
Switzerland | CHF127.15 Billion |
|
JBS N.V.
NYSE:JBS
|
USA | $248.34 Billion |
|
MEIJI HLD.UN.ADR 1/4 O.N.
F:3M00
|
Germany | €1.23 Trillion |
|
CSPC Innovation Pharmaceutical Co Ltd Class A
SHE:300765
|
China | CN¥6.21 Billion |
|
ORKLA ADR/1 NK 625
F:OKL0
|
Germany | €88.70 Billion |
|
Tingyi (Cayman Islands) Holding Corp
F:TYG
|
Germany | €54.94 Billion |
|
Yantai China Pet Foods Co Ltd
SHE:002891
|
China | CN¥6.24 Billion |
|
Yihai International Holding Ltd
F:YIR
|
Germany | €5.36 Billion |
JiangXi Tianxin Pharm Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 5.08 | 6.52 | 14.72 |
| Quick Ratio | 4.10 | 5.11 | 13.01 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥2.24 Billion | CN¥2.35 Billion | CN¥2.99 Billion |
JiangXi Tianxin Pharm Co Ltd - Advanced Valuation Insights
This section examines the relationship between JiangXi Tianxin Pharm Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.99 |
| Latest Market Cap to Assets Ratio | 0.24 |
| Asset Growth Rate (YoY) | 10.5% |
| Total Assets | CN¥6.19 Billion |
| Market Capitalization | $1.47 Billion USD |
Valuation Analysis
Below Book Valuation: The market values JiangXi Tianxin Pharm Co Ltd's assets below their book value (0.24x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: JiangXi Tianxin Pharm Co Ltd's assets grew by 10.5% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for JiangXi Tianxin Pharm Co Ltd (2020–2025)
The table below shows the annual total assets of JiangXi Tianxin Pharm Co Ltd from 2020 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥6.19 Billion ≈ $905.75 Million |
+10.47% |
| 2024-12-31 | CN¥5.60 Billion ≈ $819.94 Million |
+10.08% |
| 2023-12-31 | CN¥5.09 Billion ≈ $744.85 Million |
+8.76% |
| 2022-12-31 | CN¥4.68 Billion ≈ $684.83 Million |
+58.52% |
| 2021-12-31 | CN¥2.95 Billion ≈ $432.01 Million |
+1.27% |
| 2020-12-31 | CN¥2.92 Billion ≈ $426.60 Million |
-- |
About JiangXi Tianxin Pharm Co Ltd
JiangXi Tianxin Pharmaceutical Co., Ltd. produces and sells vitamins in China. The company offers products of vitamin B6, vitamin B1, Vitamin D3, pyridoxine hydrochloride CD grade, thiamine nitrate DC grade, folic acid, biotin, ascorbyl palmitate, vitamin E 500, a-acetyl-"-butyrolactone, and vitamin D3 for use as bulk pharmaceutical chemicals, API, food additives, and feed additives, as well as i… Read more